The leading example is retatrutide from Eli Lilly, which in an 80-week phase 3 trial lowered weight by 25.0% on its top dose, against 3.9% on placebo.1 It has no U.S. label from its maker on DailyMed as of November 20, 2026.2
The three receptors
- GLP-1. The target of every GLP-1 medicine. Activating it raises insulin, lowers glucagon, slows the stomach and reduces food intake.3
- GIP. The second incretin hormone. Tirzepatide added it to GLP-1 and became the first approved dual GIP and GLP-1 receptor agonist.4
- Glucagon. A pancreatic hormone that acts mainly on the liver. Survodutide and mazdutide pair it with GLP-1; a trial of survodutide in fatty liver disease found large drops in liver fat.5
A triple agonist combines all three. The idea is to add the effects of the dual agonists in one weekly injection. The trials so far measure the result as a whole; they cannot say how much each receptor contributes.
What retatrutide has shown
In the 2023 phase 2 trial, 338 adults with obesity or overweight took retatrutide or placebo once a week for 48 weeks. Weight fell by 8.7% on 1 mg, 17.1% on 4 mg, 22.8% on 8 mg and 24.2% on 12 mg, against 2.1% on placebo, and 83% on 12 mg lost at least 15%.6
In TRIUMPH-1, the phase 3 trial published in 2026, 2,339 adults with obesity and without diabetes took 4, 9 or 12 mg, or placebo, for 80 weeks. Weight fell by 17.6%, 23.7% and 25.0%, against 3.9%. The trial also had two built-in subgroups. In 574 people with knee osteoarthritis, knee pain on a 10-point scale fell by 3.5 and 3.6 points on 9 and 12 mg, against 1.9 on placebo. In 243 people with sleep apnea, breathing pauses and shallow breaths fell by 34.3 and 31.7 an hour, against 9.9 on placebo.1
One, two, three receptors
The chart above lines up the top dose of each kind in its own main trial. Semaglutide 2.4 mg reached 14.9% over 68 weeks, tirzepatide 15 mg 20.9% over 72 weeks, and retatrutide 12 mg 25.0% over 80 weeks.1,7 The order is suggestive, but the trials differ in length, people and design, and only one of the steps, tirzepatide against semaglutide, has been tested head to head: in SURMOUNT-5, weight fell by 20.2% against 13.7%.8
What is still open
Several questions remain in the sources we read. No trial has compared retatrutide with tirzepatide directly. No cardiovascular outcome result is reported. And TRIUMPH-1 enrolled only people without diabetes, so how a triple agonist performs at phase 3 scale in type 2 diabetes is not covered here.1 Until those answers and a label exist, the approved choices remain the single and dual agonists; our page on Mounjaro and Zepbound covers the dual one.
Side effects
In the phase 2 trial, the most common side effects were in the stomach and gut; they rose with the dose, were mostly mild to moderate, and eased with a lower starting dose. Heart rate rose with the dose, peaked at 24 weeks and then declined.6 The phase 3 report also names stomach and gut events as the most common.1
Triple agonists sold online
Retatrutide's trial results have drawn sellers. DailyMed lists 10 product labels for retatrutide pens and powders from one Chinese e-commerce company, marked "Export only".2 A listing is not an FDA approval. The FDA's warnings about unapproved GLP-1 products apply to anything sold that way.9
Sources
- Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a triple hormone receptor agonist, for treatment of obesity (TRIUMPH-1). N Engl J Med 2026;395:1781-1793. Funded by Eli Lilly. doi:10.1056/NEJMoa2604169
- DailyMed, U.S. National Library of Medicine. Search for "retatrutide", 10 results, all from Guangzhou Yixin Cross-border E-commerce Co., Ltd., marketing status "Export only"; read November 20, 2026. dailymed.nlm.nih.gov
- Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 2018;27:740-756. doi:10.1016/j.cmet.2018.03.001
- Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes. Cardiovasc Diabetol 2022;21:169. doi:10.1186/s12933-022-01604-7
- Kaplan LM, Startseva E, le Roux CW, et al. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD. Nat Med 2026;32:2948-2958. doi:10.1038/s41591-026-04479-3
- Jastreboff AM, Kaplan LM, Fr铆as JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med 2023;389:514-526. doi:10.1056/NEJMoa2301972
- WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026, section 14; and ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026, section 14. U.S. Food and Drug Administration. accessdata.fda.gov
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med 2025;393:26-36. nejm.org
- U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Content current as of October 1, 2026. fda.gov
Related analyses
Ozempic vs Zepbound: two drugs, two labels, and the trials that compared them
Mounjaro vs Zepbound: the same drug under two labels, compared by use, results and price
Nausea on a GLP-1: how common, how long, when it peaks and what helps
Compounded semaglutide and tirzepatide in 2026: what FDA allows, what it has reported, and what to check
Log any GLP-1 medicine you take and see your doses, weight and symptoms together.
Open Dose Insider